Understanding Over-the-Counter Tadalafil Regulations
Sildenafil and tadalafil were first approved for treatment of ED in 1998 and 2002, respectively. In recent years, both medicines have increasingly been made available as Non-Prescription (non- Rx) or Over-The-Counter (OTC) medication; sildenafil is available via pharmacists without prescription for treatment of ED in New Zealand since October, 2014 and as a non-prescription medication in Poland since May 2016, in the United Kingdom (UK) since March, 2018 via pharmacy, in Norway since August, 2019 and in Ireland since January, 2021.
Tadalafil half life
At the time of data retrieval for this analysis, data were current through 01 May 2024. Sanofi Consumer Healthcare’s (CHC) pharmacovigilance database holds full case information for all ICSRs reported for Sanofi medicinal products from worldwide sources. ICSRs concerning sildenafil are not systematically collected in this database because Sanofi does not hold tadacip 20 mg tadalafil any marketing authorizations for sildenafil products. Currently, UK is the only country where Sanofi is marketing authorization holder and has launched a tadalafil product. In accordance with applicable regulatory requirements, ICSRs are entered into this database not only if they concern a Sanofi CHC product, but also if a Sanofi CHC product cannot be ruled out based on the reported information.
Less common
Therefore, cases potentially concerning non-Sanofi CHC or not belonging to nonprescription tadalafil products might be stored in this database. The cut-off date for this database was 30 June, 2024. Data retrievals and selection of relevant ICSRs FAERS, EVDAS and SMARS were queried for ICSRs where sildenafil was reported as a suspect or interacting drug and that had been initially entered into the respective database on or after 01 Jan, 2010. This date was chosen to allow for retrieval of ICSRs occurring with prescribed medicine that could serve as a baseline for comparison with ICSRs reported after the non-Rx/OTC switch. FAERS, EVDAS were also queried for ICSRs concerning tadalafil based on the same criteria.
Tadalafil: what you need to know
Sanofi CHC’s global pharmacovigilance database was queried for any ICSRs concerning tadalafil as suspect drug. Data from FAERS, EVDAS and Sanofi CHC’s global pharmacovigilance database were downloaded as Microsoft Excel® files (ICSR line listings). The ISCR listing resulting from the SMARS website query was also transferred into Excel®. Excel® was used to organize, classify, tabulate and visualize retrieved ICSRs. In line with the research questions, retrieved cases concerning sildenafil were included for further analysis only if they originated from Ireland, New Zealand, Norway, Poland or the UK. Tadalafil is available as OTC medication for treatment of ED in Poland since March, 2022 and as non-Rx in the UK since June, 2023.
| Product | Dosage | Quantity + Bonus | Price | |
|---|---|---|---|---|
| Cialis Generic | 10mg | 270 + 10 Pills | 308.71€ 294.01€ | |
| Cialis Generic | 40mg | 180 + 10 Pills | 277.29€ 264.09€ | |
| Cialis Generic | 40mg | 120 + 8 Pills | 206.98€ 197.12€ | |
| Cialis Generic | 10mg | 90 + 6 Pills | 146.17€ 139.21€ | |
| Cialis Generic | 20mg | 20 Pills | 54.72€ 52.11€ | |
| Cialis Generic | 2.5mg | 120 + 6 Pills | 128.93€ 122.79€ | |
| Cialis Generic | 5mg | 120 + 6 Pills | 132.92€ 126.59€ | |
| Cialis Generic | 2.5mg | 270 + 10 Pills | 199.64€ 190.13€ | |
| Tadalista Super Active | 20mg | 90 + 10 Pills | 314.14€ 299.18€ | |
| Tadalista Super Active | 20mg | 60 + 8 Pills | 230.32€ 219.35€ | |
| Tadalista Super Active | 20mg | 180 + 20 Pills | 521.59€ 496.75€ |
In this context, Sanofi is considering applications in further countries for changing the classification for the supply of their tadalafil products from “medicinal product subject to medical prescription” to “medicinal product not subject to medical prescription”. In the context of the evaluation of the suitability for classification of sildenafil and tadalafil products as non-prescription medicines, the purpose of this analysis was to assess postmarketing pharmacovigilance data from open access databases for any evidence that the recent switches of sildenafil and tadalafil from prescription-only to non-prescription status in the above-mentioned countries had an impact on the safety profile of these medicines or resulted in new safety concerns. Specifically, the first objective of this analysis was to describe trends in the frequency of Individual Case Safety Reports (ICSRs) over time (i.e., pre and post non-Rx or OTC switch) in those countries where sildenafil or tadalafil have already undergone through non- Rx or OTC switch.
Reassuring Assessment
The second objective was to explore whether these switches from prescription to non-prescription status were associated with any changes to the characteristics of the ICSRs, such as the types, seriousness or outcomes of reported Adverse Drug Reactions (ADRs), or evidence of incorrect use such as concomitant use of contra-indicated drugs. The European Medicines Agency’s (EMA) EudraVigilance (EV) database, the United States FAERS and the SMARS database of New Zealand’s Centre for Adverse Reactions Monitoring (CARM) were queried for ICSRs concerning sildenafil or tadalafil. Of note, regulatory requirements may require marketing authorization holders to report ICSRs (in particular those describing serious ADRs) into multiple databases. Consequently, significant overlaps exist for these three databases. EV is the system for managing and analyzing information on suspected ADRs to medicines which have been authorized or are being studied in clinical trials in the European Economic Area (EEA). The system is operated by EMA on behalf of the European medicines regulatory network. As a crude approximation, the database includes serious and non-serious ICSRs reported from an EEA country, whereas only ICSRs from non-EEA countries are generally captured only if they describe serious ADRs. For this analysis, a Level 1 query of the EVDAS was performed. This query provides case level outputs of the ICSR receipt date, patient demographics (age group and sex), tradename, active ingredient, indication, treatment duration, dose and route of administration of suspect and interacting medicinal product(s), concomitant drugs, as well as Medical Dictionary for Regulatory Activities (MedDRA) Preferred Terms (PT), seriousness and outcome of the reported ADRs (Appendix 1). Country of reporting is not displayed in Level 1 retrievals but can generally be inferred from the Worldwide Unique Case Identification number.
- To buy tadalafil legally in the UK, a consultation with a doctor is usually needed.
- Some online clinics offer prescriptions after online consultations.
- Be cautious of unverified online vendors claiming OTC tadalafil in the UK.
- Insurance policies do not cover unprescribed tadalafil purchases.
- The UK market maintains strict controls over PDE5 inhibitors like tadalafil.
Case narratives or information on patient medical history, comorbidities, reporter causality assessments or the mode of dispensing 10 mg tadalafil of the suspect drug (prescription or non-prescription/OTC) are not available. For this analysis, data were retrieved with a cut-off date of 30 April, 2024. The FAERS is a database that contains ICSRs reporting suspected ADRs, medication errors and product quality complaints resulting in ADRs that were submitted to FDA by marketing authorization holders, healthcare professionals and consumers.
How Cialis Works
Sildenafil and tadalafil were first approved for treatment of ED in 1998 and 2002, respectively. In recent years, both medicines have increasingly been made available as Non-Prescription (non- Rx) or Over-The-Counter (OTC) medication; sildenafil is available via pharmacists without prescription for treatment of ED in New Zealand since October, 2014 and as a non-prescription medication in Poland since May 2016, in the United Kingdom (UK) since March, 2018 via pharmacy, in Norway since August, 2019 and in Ireland since January, 2021. Tadalafil is available as OTC medication for treatment of ED in Poland since March, 2022 and as non-Rx in the UK since June, 2023. In this context, Sanofi is considering applications in further countries for changing the classification for the supply of their tadalafil products from “medicinal product subject to medical prescription” to “medicinal product not subject to medical prescription”. In the context of the evaluation of the suitability for classification of sildenafil and tadalafil products as non-prescription medicines, the purpose of this analysis was to assess postmarketing pharmacovigilance data from open access databases for any evidence that the recent switches of sildenafil and tadalafil from prescription-only to non-prescription status in the above-mentioned countries had an impact on the safety profile of these medicines or resulted in new safety concerns.
What can I take to enhance Cialis?
Specifically, the first objective of this analysis was to describe trends in the frequency of Individual Case Safety Reports (ICSRs) over time (i.e., pre and post non-Rx or OTC switch) in those countries where sildenafil or tadalafil have already undergone through non- Rx or OTC switch. The second objective was to explore whether these switches from prescription to non-prescription status were associated with any changes to the characteristics of the ICSRs, such as the types, seriousness or outcomes of reported Adverse Drug Reactions (ADRs), or evidence of incorrect use such as concomitant use of contra-indicated drugs. The European Medicines Agency’s (EMA) EudraVigilance (EV) database, the United States FAERS and the SMARS database of New Zealand’s Centre for Adverse Reactions Monitoring (CARM) were queried for ICSRs concerning sildenafil or tadalafil. Of note, regulatory requirements may require marketing authorization holders to report ICSRs (in particular those describing serious ADRs) into multiple databases. Consequently, significant overlaps exist for these three databases.
Kamagra Soft Tabs
EV is the system for managing and analyzing information on suspected ADRs to medicines which have been authorized or are being studied in clinical trials in the European Economic Area (EEA). The system is operated by EMA on behalf of the European medicines regulatory network. As a crude approximation, the database includes serious and non-serious ICSRs reported from an EEA country, whereas only ICSRs from non-EEA countries are generally captured only if they describe serious ADRs. For this analysis, a Level 1 query of the EVDAS was performed. This query provides case level outputs of the ICSR receipt date, patient demographics (age group and sex), tradename, active ingredient, indication, treatment duration, dose and route of administration of suspect and interacting medicinal product(s), concomitant drugs, as well as Medical Dictionary for Regulatory Activities (MedDRA) Preferred Terms (PT), seriousness and outcome of the reported ADRs (Appendix 1). The database includes serious and non-serious ICSRs reported from the US, whereas ICSRs from ex-US are generally captured only if they describe serious ADRs. Limited public access to FAERS is possible through the FAERS Public Dashboard, which allows for case level access to ADR reports.
- Tadalafil is generally prescription-only in the UK; OTC access is limited.
- Some online sources claim tadalafil can be purchased OTC but illegitimate.
- UK law restricts tadalafil sales; buying without prescription may be illegal.
- Consulting a healthcare provider is recommended before using tadalafil.
- OTC sales of tadalafil are not officially authorized in the UK.
Case information includes originating country and receipt date of the report, patient age and sex, tradename, active ingredient and indication of the suspect medicinal product(s), concomitant drugs, MedDRA PTs of reported ADRs, as well as ADR onset date, seriousness and outcomes (Appendix 1). Case narratives or information on patient medical history, comorbidities, reporter causality assessments or the mode of dispensing are not available. The FAERS Public Dashboard is updated on a quarterly basis.
| Availability Status | Legal Status | Purchase Locations | Online Purchase Allowed | Age Restrictions |
|---|---|---|---|---|
| Not OTC | Prescription | Pharmacies, Online | No | 18+ |
| Restricted OTC | Some products | UK Pharmacies | Not officially allowed | 18+ |
| Not Legal | Prescription only | UK Hospitals | No | 18+ |
| Limited Access | Special license | Clinics | No | 18+ |
At the time of data retrieval for this analysis, data were current through 31 March, 2024.
- The UK does not recognize OTC availability of tadalafil as standard practice.
- Tadalafil should be used only under supervision for optimal safety.
- Many unverified online sources claiming OTC sales are misleading.
- Pharmacists are unable to supply tadalafil OTC due to legal restrictions.
- Always prioritize health and legality when considering tadalafil purchase.
SMARS is a publicly available query tool of New Zealand’s national pharmacovigilance database (Appendix 5). SMARS provides limited case level information on serious and non-serious ICSRs reported from New Zealand, including receipt date, patient age and sex, active ingredient of suspect and concomitant medicine(s) and the MedDRA PTs of reported ADRs (Appendix 1). Case narratives or information on drug indications, mode of dispensing, ADR seriousness or outcomes, patient medical history or comorbidities or reporter causality assessments are not available. Reports from other countries are not included. SMARS is updated on a monthly basis. At the time of data retrieval for this analysis, data were current through 01 May 2024. Sanofi Consumer Healthcare’s (CHC) pharmacovigilance database holds full case information for all ICSRs reported for Sanofi medicinal products from worldwide sources. ICSRs concerning sildenafil are not systematically collected in this database because Sanofi does not hold tadacip 20 mg tadalafil any marketing authorizations for sildenafil products. Currently, UK is the only country where Sanofi is marketing authorization holder and has launched a tadalafil product. In accordance with applicable regulatory requirements, ICSRs are entered into this database not only if they concern a Sanofi CHC product, but also if a Sanofi CHC product cannot be ruled out based on the reported information. Therefore, cases potentially concerning non-Sanofi CHC or not belonging to nonprescription tadalafil products might be stored in this database.
| Aspect | OTC Tadalafil | Prescribed Tadalafil |
|---|---|---|
| Average Cost | £8 - £20 per pack | £20 - £50+ per consultation + medication |
| Insurance Coverage | Usually not covered | Often covered or subsidized |
| Convenience | Purchase directly, quick access | Requires doctor visit |
The cut-off date for this database was 30 June, 2024. Data retrievals and selection of relevant ICSRs FAERS, EVDAS and SMARS were queried for ICSRs where sildenafil was reported as a suspect or interacting drug and that had been initially entered into the respective database on or after 01 Jan, 2010. This date was chosen to allow for retrieval of ICSRs occurring with prescribed medicine that could serve as a baseline for comparison with ICSRs reported after the non-Rx/OTC switch.
- Tadalafil's legal status depends on UK drug classification laws.
- OTC availability outside the UK may not be valid or safe in the UK.
- Many online vendors target UK customers for unregulated tadalafil sales.
- High-quality tadalafil requires proper medical dosing and monitoring.
- Using unprescribed tadalafil can interfere with other medications or health conditions.
FAERS, EVDAS were also queried for ICSRs concerning tadalafil based on the same criteria. Sanofi CHC’s global pharmacovigilance database was queried for any ICSRs concerning tadalafil as suspect drug. Data from FAERS, EVDAS and Sanofi CHC’s global pharmacovigilance database were downloaded as Microsoft Excel® files (ICSR line listings).
How it works
“non-Rx/OTC cases” based on ADR onset date or report date. Therefore, the annual number of ICSRs over time (i.e., pre and post non-Rx/OTC switch) was displayed and assessed per country, acknowledging that ICSRs reported after the non-Rx/OTC switch date would comprise an unknown mix of ADRs occurring in prescription and non-prescription settings. The ISCR listing resulting from the SMARS website query was also transferred into Excel®. Excel® was used to organize, classify, tabulate and visualize retrieved ICSRs.
Overdose/Missed Dose
Cases concerning tadalafil were included for further analysis only if they originated from Poland or the UK. ICSRs concerning females, patients younger than 18 years of age, or describing use of sildenafil or tadalafil in patients with PAH (as defined in Appendix 2) were excluded from all analyses. Within the FAERS dataset, almost half of the retrieved, relevant ICSRs were suggestive for duplicates (i.e., ICSRs reporting the same country of origin, patient age and sex, suspect and concomitant drugs, ADRs and/or ADR onset dates, but received from different marketing authorization holders and with different Worldwide Unique Case Identification Numbers). Because full case information tadalafil sale was not accessible through the FAERS Public Dashboard, definitive identification of case duplicates was not possible. Therefore, suspected duplicates were not categorically excluded from the FAERS dataset.
Incidence not known
However, probable duplicates were flagged and the effect of excluding these cases on reporting patterns was explored in the country-specific analyses. In the EVDAS Level 1 retrievals, exact patient age and ADR onset dates are not provided at all, thereby prohibiting reliable identification of potential duplicates. There was no indication of the presence of duplicates in Sanofi CHC’s global pharmacovigilance database or, from the limited information available, in the SMARS dataset. Number of ICSRs and reporting rates over time The mode of dispensing of the suspect drug is not reported in the outputs of any of the queried databases and could also not be reliably established from the trade name of the suspect PDE5i, which was missing in approximately 52.5% of the relevant ICSRs of tadalafil retrieved from Sanofi CHC’s company database. Unknown delays between dispense, administration, ADR onset and ADR reporting also prohibited reliable classification of ICSRs as “prescription cases” vs. In line with the research questions, retrieved cases concerning sildenafil were included for further analysis only if they originated from Ireland, New Zealand, Norway, Poland or the UK. Cases concerning tadalafil were included for further analysis only if they originated from Poland or the UK. ICSRs concerning females, patients younger than 18 years of age, or describing use of sildenafil or tadalafil in patients with PAH (as defined in Appendix 2) were excluded from all analyses.
Online Doctor Service
Country of reporting is not displayed in Level 1 retrievals but can generally be inferred from the Worldwide Unique Case Identification number. Case narratives or information on patient medical history, comorbidities, reporter causality assessments or the mode of dispensing 10 mg tadalafil of the suspect drug (prescription or non-prescription/OTC) are not available. For this analysis, data were retrieved with a cut-off date of 30 April, 2024. The FAERS is a database that contains ICSRs reporting suspected ADRs, medication errors and product quality complaints resulting in ADRs that were submitted to FDA by marketing authorization holders, healthcare professionals and consumers. The database includes serious and non-serious ICSRs reported from the US, whereas ICSRs from ex-US are generally captured only if they describe serious ADRs.
Cialis Professional
Limited public access to FAERS is possible through the FAERS Public Dashboard, which allows for case level access to ADR reports. Case information includes originating country and receipt date of the report, patient age and sex, tradename, active ingredient and indication of the suspect medicinal product(s), concomitant drugs, MedDRA PTs of reported ADRs, as well as ADR onset date, seriousness and outcomes (Appendix 1). Case narratives or information on patient medical history, comorbidities, reporter causality assessments or the mode of dispensing are not available. The FAERS Public Dashboard is updated on a quarterly basis. At the time of data retrieval for this analysis, data were current through 31 March, 2024.
What is Cialis Together?
SMARS is a publicly available query tool of New Zealand’s national pharmacovigilance database (Appendix 5). SMARS provides limited case level information on serious and non-serious ICSRs reported from New Zealand, including receipt date, patient age and sex, active ingredient of suspect and concomitant medicine(s) and the MedDRA PTs of reported ADRs (Appendix 1). Case narratives or information on drug indications, mode of dispensing, ADR seriousness or outcomes, patient medical history or comorbidities or reporter causality assessments are not available. Reports from other countries are not included. SMARS is updated on a monthly basis. Within the FAERS dataset, almost half of the retrieved, relevant ICSRs were suggestive for duplicates (i.e., ICSRs reporting the same country of origin, patient age and sex, suspect and concomitant drugs, ADRs and/or ADR onset dates, but received from different marketing authorization holders and with different Worldwide Unique Case Identification Numbers). Because full case information tadalafil sale was not accessible through the FAERS Public Dashboard, definitive identification of case duplicates was not possible. Therefore, suspected duplicates were not categorically excluded from the FAERS dataset. However, probable duplicates were flagged and the effect of excluding these cases on reporting patterns was explored in the country-specific analyses. In the EVDAS Level 1 retrievals, exact patient age and ADR onset dates are not provided at all, thereby prohibiting reliable identification of potential duplicates. There was no indication of the presence of duplicates in Sanofi CHC’s global pharmacovigilance database or, from the limited information available, in the SMARS dataset. Number of ICSRs and reporting rates over time The mode of dispensing of the suspect drug is not reported in the outputs of any of the queried databases and could also not be reliably established from the trade name of the suspect PDE5i, which was missing in approximately 52.5% of the relevant ICSRs of tadalafil retrieved from Sanofi CHC’s company database. Unknown delays between dispense, administration, ADR onset and ADR reporting also prohibited reliable classification of ICSRs as “prescription cases” vs. “non-Rx/OTC cases” based on ADR onset date or report date. Therefore, the annual number of ICSRs over time (i.e., pre and post non-Rx/OTC switch) was displayed and assessed per country, acknowledging that ICSRs reported after the non-Rx/OTC switch date would comprise an unknown mix of ADRs occurring in prescription and non-prescription settings.